BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 27232207)

  • 21.
    Trivisonno LF; Sgarbossa N; Alvez GA; Fieiras C; Escobar Liquitay CM; Jung JH; Franco JVA
    Investig Clin Urol; 2021 Sep; 62(5):520-534. PubMed ID: 34488251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies.
    Mantovani F
    Minerva Urol Nefrol; 2010 Dec; 62(4):335-40. PubMed ID: 20944533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract.
    Habib FK; Wyllie MG
    Prostate Cancer Prostatic Dis; 2004; 7(3):195-200. PubMed ID: 15289814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
    Zlotta AR; Teillac P; Raynaud JP; Schulman CC
    Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of Serenoa repens, lycopene and selenium on prostatic disease: evidences and hypotheses.
    Magri V; Trinchieri A; Perletti G; Marras E
    Arch Ital Urol Androl; 2008 Jun; 80(2):65-78. PubMed ID: 18683812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
    BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serenoa repens and benign prostatic hyperplasia: no more effective than placebo.
    Prescrire Int; 2010 Aug; 19(108):181-2. PubMed ID: 20941857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis.
    Wang X; Wang X; Li S; Meng Z; Liu T; Zhang X
    PLoS One; 2014; 9(9):e107593. PubMed ID: 25216271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia.
    Dreikorn K
    World J Urol; 2002 Apr; 19(6):426-35. PubMed ID: 12022711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
    Oelke M; Giuliano F; Mirone V; Xu L; Cox D; Viktrup L
    Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia.
    Lee J; Andriole G; Avins A; Crawford ED; Foster H; Kaplan S; Kreder K; Kusek J; McCullough A; McVary K; Meleth S; Naslund M; Nickel JC; Nyberg L; Roehrborn C; Dale Williams O; Barry M
    Clin Trials; 2009 Dec; 6(6):628-36. PubMed ID: 20007408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis.
    Debruyne F; Boyle P; Calais Da Silva F; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP; Schulman CC
    Eur Urol; 2004 Jun; 45(6):773-9; disucssion 779-80. PubMed ID: 15149751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pygeum africanum for benign prostatic hyperplasia.
    Wilt T; Ishani A; Mac Donald R; Rutks I; Stark G
    Cochrane Database Syst Rev; 2002; 1998(1):CD001044. PubMed ID: 11869585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Associating Serenoa repens, Urtica dioica and Pinus pinaster. Safety and efficacy in the treatment of lower urinary tract symptoms. Prospective study on 320 patients].
    Pavone C; Abbadessa D; Tarantino ML; Oxenius I; LaganĂ  A; Lupo A; Rinella M
    Urologia; 2010; 77(1):43-51. PubMed ID: 20890858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
    Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
    Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis].
    Debruyne F; Boyle P; Calais da Silva F; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP; Schulman C
    Prog Urol; 2004 Jun; 14(3):326-31. PubMed ID: 15373174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.